Editas Medicine Announces U.S. Patent and Trademark Office Decision Favorable to Broad Institute in CRISPR Interference

Ablexis Announces Perpetual License Agreement for AlivaMab Mouse with Janssen

Global Blood Therapeutics Announces Publication of Paper Describing Discovery of GBT440 in ACS Medicinal Chemistry Letters

Decibel Therapeutics Presents at 2017 Annual Association for Research in Otolaryngology (ARO) Meeting

Sage Therapeutics Advances SAGE-217 into Placebo-Controlled Phase 2 Clinical Trial in Major Depressive Disorder

Voyager Therapeutics Announces Lead Clinical Candidate Selection for Monogenic Form of Amyotrophic Lateral Sclerosis (ALS)

Editas Medicine to Present at Upcoming February Investor Conferences

Goldfinch Bio Appoints Nephrologist Louis Brenner, M.D., M.B.A. to Board of Directors

Zafgen to Present at the Leerink Partners 6th Annual Global Healthcare Conference

Eleven Biotherapeutics to Present at the 2017 BIO CEO & Investor Conference

Fulcrum Therapeutics Strengthens its Board of Directors with the Addition of Alan Ezekowitz, MBChB, D.Phil., and James J. Collins, Ph.D.

Sage Therapeutics to Participate in Upcoming February Investor Conferences

Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2016 Financial Results and Conference Call

bluebird bio Announces First Patient Treated with LentiGlobinâ„¢ Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease

CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial

First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491

MyoKardia Announces Appointment of June Lee, M.D., as Chief Operating Officer and Radhika Tripuraneni, M.D., as Vice President, Medical Affairs

Jounce Therapeutics Announces Pricing of Initial Public Offering

Voyager Therapeutics Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience

Voyager Therapeutics Announces Updates from Phase 1b Trial of VY-AADC01 for Advanced Parkinson's Disease

Global Blood Therapeutics Announces Enrollment of First Patient in Phase 3 HOPE Study in Sickle Cell Disease

Decibel Therapeutics Expands Leadership Team With World-Class Bioinformatics Scientist; Appoints Three New Members to its Board of Directors

Foundation Medicine Reports Preliminary 2016 Results

Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference

CytomX to Present at the 35th Annual J.P. Morgan Healthcare Conference

Agios Announces Key Upcoming Milestones to Support Evolution to a Commercial Stage Biopharmaceutical Company in 2017

UPDATE: CytomX Announces Time Change for its Presentation at the 35th Annual J.P. Morgan Healthcare Conference

Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference

TARIS Biomedical® Announces Positive Results from Ph1b Trial of TAR-200 (GemRIS™) in Patients with Muscle Invasive Bladder Cancer

Allena Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference

Neon Therapeutics Secures $70 Million in Series B Financing

Pliant Therapeutics Appoints Leading Academic Researcher and Industry Veteran Rik Derynck, Ph.D. As Scientific Founder

Voyager Therapeutics Elects Wendy Dixon, Ph.D. and Glenn Pierce, M.D., Ph.D. to Board of Directors

bluebird bio to Present at the 35th Annual J.P. Morgan Healthcare Conference

Editas Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference

Foundation Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference

Voyager Therapeutics Appoints Jane Pritchett Henderson as Chief Financial Officer

MyoKardia Announces Advancement to Next Phase of Global Collaboration with Sanofi

Global Blood Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference

Agios Appoints Ian Clark to Board of Directors

Agios to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017

Sage Therapeutics to Participate in Goldman Sachs Healthcare Conference

Neon Therapeutics to Present at 35th Annual J.P. Morgan Healthcare Conference

REVOLUTION Medicines Raises Additional $25 Million in Series A Financing

Sage Therapeutics Announces Initiation of Phase 2 Clinical Development for SAGE-217 in Mood Disorders

Editas Medicine Extends CRISPR Genome Editing Leadership Through Licensing of New CRISPR Technologies

Foundation Medicine Receives FDA Approval of FoundationFocusâ„¢ CDxBRCA as a Companion Diagnostic for Rubracaâ„¢ (rucaparib) for the Treatment of Women with Ovarian Cancer

Global Blood Therapeutics Added to NASDAQ Biotechnology Index

Agios Provides Update on PKR Program

bluebird bio and apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement